Atomo Diagnostics Limited (ASX:AT1)
Australia · Delayed Price · Currency is AUD | Market Cap | 16.24M +0.2% |
| Revenue (ttm) | 5.33M +40.6% |
| Net Income | -3.51M |
| EPS | -0.00 |
| Shares Out | 902.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 147,917 |
| Open | 0.0180 |
| Previous Close | 0.0180 |
| Day's Range | 0.0170 - 0.0180 |
| 52-Week Range | 0.0160 - 0.0480 |
| Beta | 1.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Atomo Diagnostics
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-testing programs; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia. [Read more]
Financial Performance
In fiscal year 2026, Atomo Diagnostics's revenue was 5.33 million, an increase of 40.65% compared to the previous year's 3.79 million. Losses were -3.51 million, -29.32% less than in 2025.
Financial StatementsNews
Atomo Diagnostics Annual report: H2 2026
Atomo Diagnostics has published its H2 2026 annual report on August 30, 2026.
Atomo Diagnostics Slides: H2 2026
Atomo Diagnostics has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 30, 2026.
Atomo Diagnostics Earnings Call Transcript: Q4 2026
Revenue grew 40% year-over-year to AUD 5.3 million, driven by HIV and Pascal OEM segments, with strong cash position and no debt. Operational upgrades and new product launches in syphilis and liver tests are expected to support continued growth into FY 2027.
Atomo Diagnostics Slides: Q4 2026
Atomo Diagnostics has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on July 23, 2026.
Atomo Diagnostics Earnings Call Transcript: Q3 2026
Q3 marked a transformative period with strong sales momentum, a strengthened balance sheet, and key regulatory wins, notably the U.S. CLIA waiver for FebriDx. The company expects significant revenue growth in Q4 and continued expansion in HIV, syphilis, and liver function testing.
Atomo Diagnostics Slides: Q3 2026
Atomo Diagnostics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on April 28, 2026.
Atomo Diagnostics Earnings Call Transcript: H1 2026
Revenue grew 6% to nearly AUD 2.2 million, with EBITDA loss halved and cash reserves at AUD 3.5 million. Pascal device orders surged 1,600% year-over-year, and new partnerships and product developments are set to drive further growth.
Atomo Diagnostics Quarterly report: H1 2026
Atomo Diagnostics has published its H1 2026 quarterly earnings report on February 25, 2026.
Atomo Diagnostics Slides: H1 2026
Atomo Diagnostics has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 25, 2026.
Atomo Diagnostics Earnings Call Transcript: Q2 2026
Quarterly revenue more than doubled to AUD 1.5 million, driven by OEM Pascal and HIV self-test growth. Cash position improved, losses narrowed, and new products and OEM customers were secured, with strong outlook for further expansion.
Atomo Diagnostics Slides: Q2 2026
Atomo Diagnostics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on January 27, 2026.
Atomo Diagnostics Earnings Call Transcript: Q1 2026
Momentum continues with strong OEM and HIV self-test sales, a robust cash position, and new product launches. Regulatory progress and expanded partnerships are expected to drive further growth, especially as syphilis and Flurry products advance.
Atomo Diagnostics Earnings release: Q1 2026
Atomo Diagnostics released its Q1 2026 earnings on October 28, 2025, summarizing the period's financial results.